Lead
Two weeks of coughing. Almost no fever. Still eating. Still going to school. But the cough will not stop.
A pediatrician says: "This might be mycoplasma pneumonia." The word pneumonia sounds alarming, yet the child seems reasonably well. How worried should you be? Is the medication working? This is the situation many parents find themselves in without enough information to make sense of it.
Mycoplasma pneumonia is often called "walking pneumonia" in English — meaning the illness is typically mild enough that the child can carry on. Many cases never require hospitalization. But mild does not mean trivial. And in Japan, there is a specific clinical problem layered on top: macrolide antibiotics, the first-line drug worldwide, face a resistance rate higher than Europe's — in epidemic years, around half of childhood infections can involve resistant strains. The situation in which "the child is on antibiotics but not improving" is not uncommon — and it has a documented cause.
The Causative Bacterium: Mycoplasma pneumoniae
The organism causing this illness, Mycoplasma pneumoniae, is an unusual bacterium. It has no cell wall, which means the entire class of β-lactam antibiotics: a major class of antibiotics including penicillins and cephalosporins that work by disrupting bacterial cell wall synthesis, ineffective against cell-wall-free organisms — penicillins, cephalosporins — has no mechanism to work against it [1]. Treatment requires drugs that interfere with protein synthesis rather than cell wall synthesis: macrolides, tetracyclines, or fluoroquinolones.
It spreads by respiratory droplet, with an incubation period of one to three weeks — longer than most common childhood respiratory infections. The extended incubation, combined with transmission in school and childcare settings, explains why peak incidence clusters in school-age children, roughly ages 5–12 [1,2]. The organism is also known to cause epidemic waves at roughly four-year intervals.
The Clinical Picture and the Limits of Diagnosis
The typical course starts with fatigue, headache, and low-grade fever, followed several days later by a dry cough that then persists for three to five weeks or more [1]. That prolonged dry cough is the distinguishing feature — it is what separates this from most other pediatric respiratory infections.
Diagnosis is not straightforward. Rapid antigen tests on throat swabs — the most commonly used bedside tool — are less sensitive than nucleic acid amplification tests (PCR or LAMP) [6]. Serum IgM antibodies rise one to two weeks after infection, which means they are often negative early in the illness. "The rapid test was negative, so it isn't mycoplasma" is not a conclusion that can be drawn; clinical judgment integrating symptoms and time course is necessary.
Chest X-ray findings (interstitial infiltrates) can precede or follow symptoms. It is not unusual to see a child with notable X-ray findings who appears relatively well.
The Macrolide Resistance Problem in Japan
First-line treatment for mycoplasma pneumonia globally is a macrolide antibiotic — clarithromycin or azithromycin [3,4]. But Japan has a documented and serious macrolide: a class of antibiotics including clarithromycin and azithromycin that inhibit bacterial protein synthesis, used as first-line treatment for Mycoplasma resistance problem rooted in point mutations: single-nucleotide changes in a gene that can confer antibiotic resistance by altering the drug's binding target in the 23S rRNA gene.
In 2005, Morozumi and colleagues reported the emergence of this resistant strain in clinical isolates [5], and it spread quickly. A study following isolates from Japanese children from 2008 to 2024 found that resistance peaked at 81.8% in 2012, fell to 14–33% in 2018–2020, then rose back to 54.1% in 2024, the first major epidemic in eight years [7]. Some facilities and periods have reported even higher figures, so resistance is not a number that can be summarized by a single value [6]. Japan currently sits above Europe but below China, South Korea, and Taiwan, where rates of 70–100% have been reported [6,7].
When a child is infected with a macrolide-resistant strain and treated with a macrolide, the fever often does not break within 48–72 hours (about 70% of resistant-strain cases are still febrile at 48 hours) [6]. If that happens, two alternative drug classes are considered:
- Tetracyclines (minocycline): Generally avoided in children under eight because of side effects such as permanent tooth staining and enamel hypoplasia; under eight, they are considered only when other drugs cannot be used or have failed [6]
- Fluoroquinolones (tosufloxacin): The only fluoroquinolone approved for children in Japan. To avoid driving resistance, routine use should be avoided; it is reserved for pneumonia where it is judged necessary [6]
If a child on macrolide treatment shows no signs of improvement within 48–72 hours of starting, the prescribing physician should be contacted promptly. The Japan Pediatric Society's guidance likewise states that macrolide efficacy can generally be judged by whether the fever resolves within two to three days of starting [6].
Complications: Not Common, But Worth Knowing
Most cases resolve on their own. A small fraction develop serious complications. These are rare but important to recognize:
- SJS: Stevens-Johnson syndrome: a rare, severe immune reaction causing widespread skin blistering and mucous membrane damage, potentially triggered by infection or medication (Stevens-Johnson syndrome): A severe mucocutaneous condition involving extensive skin and mucous membrane involvement. Mycoplasma has been documented as an associated infectious cause
- Encephalitis / meningitis: Can present as a central nervous system illness without typical respiratory symptoms — "CNS mycoplasma infection" without preceding cough
- Myocarditis / pericarditis: Rare, but potentially serious
If a child on treatment develops any of the following, prompt medical evaluation is needed: high fever returning after apparent improvement; blistering or widespread rash; new-onset headache with altered behavior or consciousness.
School Attendance
Mycoplasma pneumoniae infection is not classified as a mandatory exclusion condition under Japan's School Health and Safety Act, unlike influenza. The general approach is that a child may return to school once fever has resolved and overall condition is stable. That said, if fever persists or the cough remains intense, staying home is appropriate both for the child's sake and to limit spread. The specific decision should be made in consultation with the school and the treating physician.
Tracking the Illness at Home
Keeping a record of the illness course materially improves the information available at clinic visits.
What to record: the date cough began; presence or absence of fever and maximum temperature; character of the cough (dry vs. productive); nighttime cough severity; changes in appetite and activity level.
When to seek care: if a dry cough exceeds two weeks, a chest X-ray to assess for pneumonia is a reasonable next step.
Monitoring during treatment: if there is no improvement within 48–72 hours of starting a macrolide, report this to the prescribing physician without waiting for the next scheduled appointment.
Watchful waiting is a legitimate option in mild cases: in mild illness without signs of progression, some evidence supports resolution without antibiotics within two to four weeks [1]. Whether watchful waiting is appropriate for a given child is a conversation with the treating physician.
Summary
Mycoplasma pneumonia deserves to be taken seriously — not because it is usually severe, but because Japan's macrolide resistance rate, which swings widely and runs high in epidemic years, creates a specific clinical trap: the medication most likely to be prescribed may not work. A child on treatment who is not improving within two to three days is not just having a slow recovery; the resistance rate makes that a specific clinical concern worth raising promptly.
Tracking symptoms from the start and communicating what you observe to the physician — when the cough began, how it has changed, how the child is responding to treatment — is the most practical thing a parent can do to support good care.
References
- Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32(6):956–973. doi:10.1111/j.1574-6976.2008.00129.x. PMID: 18754792.
- Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front Microbiol. 2016;7:693. doi:10.3389/fmicb.2016.00693. PMID: 27242718.
- Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25–76. doi:10.1093/cid/cir531. PMID: 21880587.
- Committee for the Guidelines for the Management of Respiratory Infectious Diseases in Children (Ishiwada N, Shinjoh M, eds.). Guidelines for the Management of Respiratory Infectious Diseases in Children 2022 [in Japanese]. Tokyo: Kyowa Kikaku; 2022.
- Morozumi M, Hasegawa K, Kobayashi R, et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother. 2005;49(6):2302–2306. doi:10.1128/AAC.49.6.2302-2306.2005. PMID: 15917525.
- Japan Pediatric Society, Committee on Immunization and Infectious Diseases. Approach to the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children [in Japanese]. February 19, 2013; revised March 29, 2025. https://www.jpeds.or.jp/uploads/files/20250422_maikopurazuma.pdf
- Oishi T, Kenri T, Yoshioka D. Macrolide-resistant Mycoplasma pneumoniae among Japanese children from 2008 to 2024. Microorganisms. 2025;13(10):2243. doi:10.3390/microorganisms13102243. PMID: 41156703.